Given the emerging link between mesenchymal properties and GBM tumor cell survival during therapy (resistance) or following therapy (recurrence) [10,57,58], we tested whether the observed change in mesenchymal proteins with GRHL2 alone was sufficient to trigger detectable levels of apoptosis. This evidence concerns the gene GRHL2 and neoplasm.